Related Experiment Video
Updated: May 11, 2026

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research
Published on: October 22, 2014
Fasudil inhibits ER stress-induced VCAM-1 expression by modulating unfolded protein response in endothelial cells
Daiji Kawanami1, Keiichiro Matoba, Rina Okada
1Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, Minato-ku, Tokyo, Japan. daijika@jikei.ac.jp
Abstract:
The process of atherosclerosis is affected by interactions among numerous biological pathways. Accumulating evidence shows that endoplasmic reticulum (ER) stress plays a crucial role in the development of atherosclerosis. Rho-kinase is an effector of small GTP-binding protein Rho, and has been implicated as an atherogenic factor. Previous studies demonstrated that fasudil, a specific Rho-kinase inhibitor, exerts a cardioprotective effect by downregulating ER stress signaling. However, the molecular link between ER stress and Rho-kinase in endothelial cells has not been elucidated. In this study, we investigated the mechanisms by which fasudil regulates endothelial inflammation during ER stress. Tunicamycin, an established ER stress inducer, increased vascular cellular adhesion molecule (VCAM)-1 expression in endothelial cells. Intriguingly, fasudil inhibited VCAM-1 induction. From a mechanistic stand point, fasudil inhibited expression of activating transcription factor (ATF)4 and subsequent C/EBP homologous protein (CHOP) induction by tunicamycin. Furthermore, fasudil attenuated tunicamycin-induced phophorylation of p38MAPK that is crucial for the atherogenic response during ER stress. These findings indicate that Rho-kinase regulates ER stress-mediated VCAM-1 induction by ATF4- and p38MAPK-dependent signaling pathways. Rho-kinase inhibition by fasudil would be an important therapeutic approach against atherosclerosis, in particular, under conditions of ER stress.
Insights
Rho-kinase inhibition by fasudil reduces endoplasmic reticulum (ER) stress-induced inflammation in endothelial cells. This study reveals Rho-kinase regulates ER stress-mediated vascular cellular adhesion molecule-1 induction, offering a potential therapeutic strategy for atherosclerosis.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Cellular Biology
Background:
- Endoplasmic reticulum (ER) stress is increasingly recognized as a key factor in atherosclerosis development.
- Rho-kinase is implicated as an atherogenic factor, and its inhibition by fasudil shows cardioprotective effects via ER stress signaling.
- The precise molecular mechanisms linking ER stress and Rho-kinase in endothelial cells remain unclear.
Purpose of the Study:
- To investigate how fasudil regulates endothelial inflammation during ER stress.
- To elucidate the molecular pathways involved in Rho-kinase's role in ER stress-mediated endothelial dysfunction.
Main Methods:
- Utilized tunicamycin as an ER stress inducer in endothelial cells.
- Assessed the effect of fasudil on vascular cellular adhesion molecule-1 (VCAM-1) expression.
- Examined the impact of fasudil on activating transcription factor 4 (ATF4), C/EBP homologous protein (CHOP), and p38MAPK phosphorylation.
Main Results:
- Tunicamycin treatment increased VCAM-1 expression in endothelial cells.
- Fasudil significantly inhibited tunicamycin-induced VCAM-1 expression.
- Fasudil suppressed the induction of ATF4 and CHOP, and attenuated p38MAPK phosphorylation caused by tunicamycin.
Conclusions:
- Rho-kinase regulates ER stress-induced VCAM-1 expression through ATF4- and p38MAPK-dependent pathways.
- Inhibition of Rho-kinase by fasudil represents a promising therapeutic strategy for atherosclerosis, particularly in the context of ER stress.
Related Concept Videos
The Unfolded Protein Response
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Regulation of Angiogenesis and Blood Supply
Regulation of the Unfolded Protein Response
Heart Failure V: Medical Management
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors